Publications by authors named "Sampath Athukorala"
Article Synopsis
- Sirolimus-coated balloons (SCBs) show promise for treating de novo lesions, but there is limited long-term data available on their effectiveness and safety.
- This study analyzed outcomes from 771 patients who received SCBs, focusing on metrics like cardiac death, myocardial infarction, and revascularization, with a median follow-up of 640 days.
- Results indicated low rates of adverse events, including a 1.3% rate of cardiac death and 8% overall major adverse cardiac events (MACE), suggesting SCBs may be a viable treatment option in real-world settings.
Which predilatation balloons provide the best lesion preparation prior to use of drug coated balloons in de-novo lesions? Results from the PREPARE study.
Minerva Cardiol Angiol
April 2023
Background: There is a lack of data on the clinical outcomes following the use of different strategies for lesion preparation prior to the use of drug-coated balloons (DCB). In this study, we have explored the clinical outcomes between different types of predilatation balloons: semi-compliant (SB), non-compliant (NB) and scoring balloons (ScB) used when preparing de-novo lesions prior to the use of DCB.
Methods: We retrospectively evaluated all patients who underwent treatment with DCB for de-novo lesions between 2011-2019 at 4 high-volume European centres.
Drug coated balloons (DCB) are increasingly being used in coronary intervention. Most of their use is currently restricted to in stent restenosis, however, they are also being used to treat some de novo lesion subsets (especially small vessels) and in patients unable to take dual antiplatelet therapy beyond a month. Calcified lesions pose a significant challenge to coronary intervention from lesion preparation to the delivery of drug to the vessel wall.
View Article and Find Full Text PDFBackground: Angioplasty for ISR remains a challenge with relatively high rates of recurrence. Although there is a plethora of data on ISR, there is relatively less data on intra-stent-CTO. In this study, we explore the long-term clinical outcomes following angioplasty to intra-stent CTO and study the differences in clinical outcomes between three treatment-arms: POBA vs.
View Article and Find Full Text PDFBackground: Use of drug coated balloons (DCBs) in coronary intervention is escalating. There is a plethora of data on Paclitaxcel-DCB. However, when it comes of stents, Limus-drugs are preferred over Paclitaxel.
View Article and Find Full Text PDF